Oral Ribupatide Shows Up To 12.1% Weight Loss in Phase 2, Boosting Kailera's Obesity Pipeline
KLRA is trading near its 52-week low of $18.85 (2.8% above the low).
Summary
Kailera Therapeutics announced strong Phase 2 clinical trial results for its oral Ribupatide, demonstrating up to 12.1% mean weight loss at 26 weeks. An injectable version also showed up to 5.5% mean weight loss at day 29. This specific data provides significant detail to the general positive clinical updates the company announced on May 26th, following its April IPO. The 12.1% weight loss for an oral drug is a highly competitive result in the obesity market, potentially validating Kailera's pipeline and offering a substantial upside given the stock is trading near its 52-week low.
At the time of this announcement, KLRA was trading at $19.37 on NASDAQ in the Life Sciences sector. The 52-week trading range was $18.85 to $28.23. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.